So these numbers (if I understand correctly), are based on the presumed decline in use of anthracyclines of 15% moving forward. IMO, if Zantrene is adopted this projected decline is unlikely to occur. Zantrene, with its expected cardio protective/ anti cancer properties will make anthracyclines much more competitive. With cardio protection, anthracyclines will not only be prescribed more readily, they will be able to administer more cycles of treatment. There will be zero decline in use, if anything there will be an incline! This makes the $ value touted conservative if it's based on a projected 15% decline.
So these numbers (if I understand correctly), are based on the...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.22 |
Change
-0.010(0.81%) |
Mkt cap ! $202.7M | |||
| Open | High | Low | Value | Volume |
| $1.26 | $1.26 | $1.14 | $381.6K | 320.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7000 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 2171 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.17 |
Change
-0.010 ( 5.54 %) |
||||
| Open | High | Low | Volume | ||
| $1.23 | $1.23 | $1.14 | 48407 | ||
| Last updated 15.52pm 03/05/2024 ? | |||||
| RAC (ASX) Chart |